-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Outpatient clinic
-
SARS-CoV-2
-
Post COVID-19 condition
-
Pharmacological intervention
-
Plitidepsin
-
Antineoplastic agent
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Outpatient clinic
-
SARS-CoV-2
-
Post COVID-19 condition
-
Pharmacological intervention
-
Pycnogenol
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Primary care
-
SARS-CoV-2
-
Post COVID-19 condition
-
Non pharmacological intervention
-
Rehabilitation
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Outpatient clinic
-
SARS-CoV-2
-
Post COVID-19 condition
-
Non pharmacological intervention
-
Neuromodulation
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Outpatient clinic
-
SARS-CoV-2
-
Post COVID-19 condition
-
Non pharmacological intervention
-
Rehabilitation
-
Adults (18-64 years)
-
General population
-
Outpatient clinic
-
SARS-CoV-2
-
Post COVID-19 condition
-
Non pharmacological intervention
-
Immunoadsorption
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Outpatient clinic
-
SARS-CoV-2
-
Post COVID-19 condition
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Outpatient clinic
-
Intensive care unit
-
SARS-CoV-2
-
Post COVID-19 condition
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
SARS-CoV-2
-
Post COVID-19 condition
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Outpatient clinic
-
SARS-CoV-2
-
Post COVID-19 condition
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
SARS-CoV-2
-
Post COVID-19 condition